Summary
Pfizer Inc. announced on June 27, 2019, a significant addition to its Board of Directors with the election of Dr. Scott Gottlieb. Dr. Gottlieb's appointment is effective immediately and includes his assignment to two key board committees: the Regulatory and Compliance Committee and the Science and Technology Committee. This move signals Pfizer's commitment to strengthening its expertise in critical areas of drug development and market access. Dr. Gottlieb, who recently concluded his tenure as Commissioner of the U.S. Food and Drug Administration (FDA), brings a wealth of experience in regulatory affairs and public health policy. His insights are expected to be invaluable as Pfizer navigates the complex regulatory landscape and pursues advancements in its scientific and technological endeavors. Dr. Gottlieb will receive compensation consistent with Pfizer's standard policies for non-employee directors and is protected by a standard indemnification agreement.
Key Highlights
- 1Dr. Scott Gottlieb elected to Pfizer's Board of Directors, effective immediately.
- 2Dr. Gottlieb appointed to the Regulatory and Compliance Committee.
- 3Dr. Gottlieb appointed to the Science and Technology Committee.
- 4Dr. Gottlieb's extensive experience as former FDA Commissioner is a key asset.
- 5His appointment is intended to enhance expertise in regulatory and scientific matters.
- 6Dr. Gottlieb will be compensated according to the company's standard director arrangements.
- 7He will receive an indemnification agreement, a standard practice for board members.